

Qiagen partners with DiaSorin, NeuMoDx

November 2018—Qiagen has introduced an automated, CE-marked workflow for its Quanti-Feron-TB Gold Plus Blood Collection Tubes and a novel DiaSorin Liaison Test on DiaSorin's Liaison systems. The launch offers Liaison customers high-throughput detection with QFT-Plus as part of the system's broad menu, and QFT-Plus users will gain an option for full automation of laboratory handling to support TB control efforts. Customers using the new latent TB detection workflow for Liaison systems will purchase the detection components from DiaSorin and the blood collection tube kits from Qiagen. The test is available in Europe and other markets, with an expected U.S. release in 2019 and in China in 2020.

In a separate release, Qiagen and NeuMoDx Molecular announced a strategic partnership to commercialize two fully integrated systems for automation of PCR testing. Under the agreement, Qiagen will initially distribute the NeuMoDx 288 (for high throughput) and NeuMoDx 96 (for mid-throughput) in Europe and other markets outside of the United States; NeuMoDx will cover the U.S. The companies are also collaborating to implement certain Qiagen chemistries on the NeuMoDx systems. The initial assay menu will be based on the first two CE-IVD marked assays for group B *Streptococcus* and *Chlamydia trachomatis/Neisseria gonorrhoeae* infections.

The two companies have also entered into a merger agreement in which Qiagen can acquire all NeuMoDx shares not currently owned by Qiagen; it currently owns about 19.9 percent of NeuMoDx.

[Qiagen](#), +49 (2103) 2 90